Aerie Pharmaceuticals announced the launch of Rhopressa in the United States for the treatment of patients with open-angle glaucoma or ocular hypertension.
Rhopressa (netarsudil ophthalmic solution 0.02%) is now available nationally and regionally through U.S. pharmaceutical distributors, with patients having access through local pharmacies, according to a company press release.
Formulary contracts for commercial insurance coverage in 2018 and Medicare Part D coverage in 2019 are being finalized. Additionally, through the availability of a co-pay savings card programs, patients covered by
Uncategorized